Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (388)	4/17/2006 9:43:07 AM
From: tuck	Respond to of 447

>>MELVILLE, N.Y.--(BUSINESS WIRE)--April 17, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - News) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship product, Tarceva® (erlotinib), for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). The application was submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW) by Chugai Pharmaceutical, Co., Ltd., a Japanese affiliate to Roche, OSI's international partner for Tarceva. Tarceva is currently approved in the United States, the European Union, and approximately 50 countries worldwide for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. "We applaud our colleagues at Chugai and Roche for their commitment to bringing this important treatment option to lung cancer patients in Japan as quickly as possible," said Gabriel Leung, President, OSI Oncology. "We expect Japan to be among the top countries in terms of sales potential for Tarceva, and to be a key growth driver for this product." The filing is based on results of a Phase II study that confirmed the safety and efficacy of Tarceva for Japanese patients, along with the data from the NSCLC study BR.21, which compared Tarceva to placebo for the treatment of patients with advanced NSCLC after failure of at least one prior chemotherapy regimen. About Lung Cancer According to the World Health Organization, lung cancer is the most common cancer worldwide, with 1.2 million new cases annually. NSCLC accounts for almost 80 percent of all lung cancer cases. In Japan specifically, the estimated incidence of lung cancer was about 85,000 cases in 2005.<< snip Cheers, Tuck

To: Miljenko Zuanic who wrote (388)	5/20/2006 2:17:26 PM
From: tuck	Respond to of 447

>>Genentech Announces June 2 Webcast Discussion of Lucentis Data Presented at the 2006 Retinal Physician Symposium Friday May 19, 5:02 pm ET SOUTH SAN FRANCISCO, Calif., May 19 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA ) invites investors, the media and the general public to listen to an audio webcast discussing the Lucentis Phase IIIb PIER data which is to be presented at the 2006 Retinal Physician Symposium in the Bahamas on June 2, 2006. The live webcast will begin at 10:00 a.m. Pacific Time on June 2, 2006. The webcast can be accessed on Genentech's web site at gene.com and will be archived and available for replay until 5:00 p.m. Pacific Time on June 9, 2006. A telephonic replay will also be available beginning at 1:00 p.m. Pacific Time on June 2, 2006 through 5:00 p.m. Pacific Time on June 9, 2006. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 9427739.<< snip This will likely effect OSIP. My June 30 calls I used to hedge my little position expired worthless, so I will look for a bounce to rehedge. The investment community is watching this, and if there is a rise in OSI price near-term, I'd have to think it was anticipation of less than stellar data out of PIER. It is not something I'd want to gamble on, hence the hedging on such a rise. Unless someone has a reasonable rationale for expecting less than stellar data out of PIER. I'm all ears. Cheers, Tuck